GlassScriptPhysician profile
Cranford L Scott
NPI 1265437925
$7,796.70
in general payments reported to CMS, 2019-2025
36 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,096 · 2020: $951 · 2021: $1,244 · 2022: $1,062 · 2023: $1,057 · 2024: $901 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,443.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $970.31 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $953.75 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Astrazeneca Pharmaceuticals LP | $686.36 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $678.11 | 2021-2025 | |
| Lilly USA, LLC | $505.00 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $410.20 | 2019-2022 | |
| Electromed, INC. | $367.66 | 2025 | Smartvest |
| Arbor Pharmaceuticals, INC. | $323.88 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $323.43 | 2019-2023 | Xarelto |
| Pfizer INC. | $299.17 | 2019-2025 | |
| Esperion Therapeutics, INC. | $267.04 | 2020-2024 | Nexletol |
| Gilead Sciences, INC. | $237.68 | 2019-2023 | |
| Abbvie INC. | $235.78 | 2021-2024 | Vraylar |
| Novartis Pharmaceuticals Corporation | $169.62 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $140.00 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $139.78 | 2020-2024 | Afrezza |
| Horizon Therapeutics Plc | $127.06 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $118.05 | 2019-2023 | Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.00 | 2019-2022 | |
| Amarin Pharma, INC. | $111.40 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $72.85 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $71.21 | 2020-2021 | |
| Dexcom, INC. | $60.89 | 2022-2023 | Dexcom G6 Transmitter |
| Vertiflex, INC. | $46.75 | 2019 | |
| Allergan, INC. | $45.03 | 2019-2020 | |
| Abbott Laboratories | $44.99 | 2023 | Freestyle Libre 2, Proclaim |
| Ultragenyx Pharmaceutical INC. | $40.79 | 2022-2023 | |
| Zealand Pharma US, INC. | $40.20 | 2020 | |
| Hikma Pharmaceuticals USA | $37.09 | 2022 | |
| Azurity Pharmaceuticals, INC. | $30.65 | 2025 | Edarbi |
| Corcept Therapeutics | $28.58 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $22.99 | 2021 | |
| Eisai INC. | $19.18 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $18.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.57 | 2019 | |
| Opko Pharmaceuticals, LLC | $16.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cranford Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.